Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 323,320 |
|
|||||
| News | - | ||||||
| Day High | 3.42 | Low High |
|||||
| Day Low | 3.21 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ARCA Biopharma Inc | ABIO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.135 | 4.15% | 3.385 | 11:30:50 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.24 | 3.21 | 3.42 | 3.25 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 531 | 323,320 | $ 3.39 | $ 1,094,851 | - | 1.56 - 3.88 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:31:18 | 7 | $ 3.385 | USD |
ARCA Biopharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 49.3M | 14.50M | - | 0 | -5.34M | -0.37 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ARCA Biopharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABIO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.29 | 3.42 | 3.12 | 3.24 | 219,615 | 0.095 | 2.89% |
| 1 Month | 1.78 | 3.88 | 1.69 | 3.24 | 4,567,103 | 1.61 | 90.17% |
| 3 Months | 1.66 | 3.88 | 1.57 | 3.22 | 1,514,717 | 1.73 | 103.92% |
| 6 Months | 2.05 | 3.88 | 1.56 | 3.19 | 716,457 | 1.34 | 65.12% |
| 1 Year | 1.97 | 3.88 | 1.56 | 3.16 | 367,024 | 1.42 | 71.83% |
| 3 Years | 3.34 | 3.90 | 1.56 | 2.97 | 228,233 | 0.045 | 1.35% |
| 5 Years | 5.67 | 22.00 | 1.56 | 7.34 | 395,076 | -2.29 | -40.30% |
ARCA Biopharma Description
| ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. |
